Skip NavigationSkip to Content

CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification

  1. Author:
    Okoye, Afam A
    Duell, Derick D
    Fukazawa, Yoshinori
    Varco-Merth, Benjamin
    Marenco, Alejandra
    Behrens, Hannah
    Chaunzwa, Talent Morgan
    Selseth, Andrea N
    Gilbride, Roxanne M
    Shao, Jason
    Edlefsen, Paul T
    Geleziunas, Romas
    Pinkevych, Mykola
    Davenport, Miles P
    Busman-Sahay, Kathleen
    Nekorchuk, Michael D
    Park, Haesun
    Smedley, Jeremy V
    Axthelm, Michael K
    Estes, Jacob D
    Hansen, Scott G
    Keele,Brandon
    Lifson,Jeffrey
    Picker, Louis J
  2. Author Address

    Vaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, United States of America., Vaccine and Gene Therapy Institute, Oregon Health and Science University, Beaverton, United States of America., Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, United States of America., Clinical Virology, Gilead Sciences, Foster City, United States of America., Kirby Institute for Infection and Immunity, University of New South Wales, Sydney, Australia., Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, United States of America., NCI at Frederick, Frederick, United States of America.,
    1. Year: 2021
    2. Date: Apr 15
    3. Epub Date: 2021 02 25
  1. Journal: The Journal of clinical investigation
    1. 131
    2. 8
  2. Type of Article: Article
  3. Article Number: e141677
  4. ISSN: 0021-9738
  1. Abstract:

    To define the contribution of CD8+ T cell responses to control of SIV reactivation during and following antiretroviral therapy (ART), we determined the effect of long-term CD8+ T cell depletion using a rhesusized anti-CD8ß monoclonal antibody (mAb) on barcoded SIVmac239 dynamics on stable ART and after ART cessation in Rhesus Macaques (RMs). Among the RMs with full CD8+ T cell depletion in both blood and tissue, there were no significant differences in the frequency of viral blips in plasma, the number of SIV RNA+ cells and the average number of RNA copies/infected cell in tissue, and levels of cell-associated SIV RNA and DNA in blood and tissue relative to control-treated RM during ART. Upon ART cessation, both CD8+ T cell-depleted and control RMs rebounded in <12 days with no difference in the time to viral rebound, or in either the number or growth rate of rebounding SIVmac239M barcode clonotypes. However, effectively CD8+ T cell-depleted RMs showed a stable ~2-log increase in post-ART plasma viremia relative to controls. These results indicate that while potent anti-viral CD8+ T cell responses can develop during ART-suppressed SIV infection, these responses effectively intercept post-ART SIV rebound only after systemic viral replication, too late to limit reactivation frequency or the early spread of reactivating SIV reservoirs.

    See More

External Sources

  1. DOI: 10.1172/JCI141677
  2. PMID: 33630764
  3. WOS: 000668203300008
  4. PII : 141677

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel